The goal of the Developmental Research Program in the Mayo Clinic SPORE in Ovarian Cancer is to support innovative, scientifically sound research projects from which findings can be translated into clinically relevant intervenfions that will reduce the burden of ovarian cancer. The Developmental Research Program will 1) foster innovafive laboratory, populafion, and clinical study proposals that have strong translafional potenfial;2) encourage and support interdisciplinary collaboration in translational research in ovarian cancer; and 3) generate new hypotheses that can be tested in larger scale research projects or clinical trials in ovarian cancer. The Developmental Research Program will provide $200,000 annually ($100,000 from the SPORE and a matching $100,000 from Mayo) to support four meritorious projects each year. Depending on the progress on a given project, there will be the possibility of a second year of support. The Developmental Research Program will ufilize a defined process to call for applicafions on an annual basis and to review submissions, ufilizing the expertise of the Internal Scientific Advisory Committee and other experienced investigators as needed. Criteria for selection will include: the likelihood that the work will impact major challenges in ovarian cancer, scientific merit, originality, translafional potential, quallficafions of the key personnel, and interactivity. It is anticipated that support of pilot projects through this program will generate new hypotheses that can be addressed in exisfing SPORE-sponsored projects or through peer-reviewed external grant support. Brief descriptions of several potenfial developmental research projects are included to demonstrate the depth and breadth of ongoing research in ovarian cancer at Mayo Clinic

Public Health Relevance

The Developmental Research Program will support studies with high potenfial to impact ovarian cancer treatment and outcome. Four projects that encourage collaborations and generate new ideas to be tested will be supported each year.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA136393-02
Application #
8112721
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
2
Fiscal Year
2010
Total Cost
$137,465
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Botuyan, Maria Victoria; Cui, Gaofeng; Drané, Pascal et al. (2018) Mechanism of 53BP1 activity regulation by RNA-binding TIRR and a designer protein. Nat Struct Mol Biol 25:591-600
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Earp, Madalene; Tyrer, Jonathan P; Winham, Stacey J et al. (2018) Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS One 13:e0197561
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wu, Chenming; Luo, Kuntian; Zhao, Fei et al. (2018) USP20 positively regulates tumorigenesis and chemoresistance through ?-catenin stabilization. Cell Death Differ 25:1855-1869
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Li, Lei; Liu, Tongzheng; Li, Yunhui et al. (2018) The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization. Oncogene 37:2422-2431
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Wu, Dongyan; Yang, Haitao; Winham, Stacey J et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63:339-348
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987

Showing the most recent 10 out of 294 publications